GluN2C/GluN2D subunit‐selective NMDA receptor potentiator CIQ reverses MK‐801‐induced impairment in prepulse inhibition and working memory in Y‐maze test in mice
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Despite ample evidence supporting the N‐methyl‐d‐aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia, progress in the development of effective therapeutics based on this hypothesis has been limited. Facilitation of NMDA receptor function by co‐agonists (d‐serine or glycine) only partially alleviates the symptoms in schizophrenia; other means to facilitate NMDA receptors are required. NMDA receptor sub‐types differ in their subunit composition, with varied GluN2 subunits (GluN2A‐GluN2D) imparting different physiological, biochemical and pharmacological properties. CIQ is a positive allosteric modulator that is selective for GluN2C/GluN2D‐containing NMDA receptor s (M ullasseril et al.). Experimental Approach: The effect of systemic administration of CIQ was tested on impairment in prepulse inhibition (PPI), hyperlocomotion and stereotypy induced by i.p. administration of MK‐801 and methamphetamine. The effect of CIQ was also tested on MK‐801‐induced impairment in working memory in Y‐maze spontaneous alternation test. Key Results: We found that systemic administration of CIQ (20 mg·kg−1, i.p.) in mice reversed MK‐801 (0.15 mg·kg−1, i.p.)‐induced, but not methamphetamine (3 mg·kg−1, i.p.)‐induced, deficit in PPI. MK‐801 increased the startle amplitude to pulse alone, which was not reversed by CIQ. In contrast, methamphetamine reduced the startle amplitude to pulse alone, which was reversed by CIQ. CIQ also partially attenuated MK‐801‐ and methamphetamine‐induced hyperlocomotion and stereotyped behaviours. Additionally, CIQ reversed the MK‐801‐induced working memory deficit in spontaneous alternation in a Y‐maze. Conclusion and Implications: Together, these results suggest that facilitation of GluN2C/GluN2D‐containing receptors may serve as an important therapeutic strategy for treating positive and cognitive symptoms in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535 · cited 10×
“Expression analysis suggest that GluN2C/GluN2D are localized to the interneurons in corticolimbic circuitry (Monyer et al., 1994; Rudolf et al., 1996; Standaert et al., 1996; Scherzer et al., 1998; Munoz et al., 1999; Xi et al., 2009), and therefore, the higher sensitivity of GluN2C/GluN2D…”
BackgroundInfluentialKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 2×
“MK-801 may lead to disinhibition of the medial prefrontal cortex circuit by preferential blockade of interneurons (Homayoun and Moghaddam, 2007) and an associated increase in glutamate release in the medial prefrontal cortex (Moghaddam et al., 1997), which may be partly responsible for the working memory deficit.”
BackgroundGuidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 2×
“…of Pharmacology (2014) 171 799–809 MK-801 may lead to disinhibition of the medial prefrontal cortex circuit by preferential blockade of interneurons (Homayoun and Moghaddam, 2007) and an associated increase in glutamate release in the medial prefrontal cortex (Moghaddam et al., 1997), which may be…”
BackgroundThe MAPK cascade is required for mammalian associative learning
Atkins, C. M., Selcher, J. C., Petraitis, J. J., Trzaskos, J. M., & Sweatt, J. D. (1998) · Nature Neuroscience · doi:10.1038/2836 · Cited by 1,083 · cited 2×
“injection was based on previous publications (Atkins et al., 1998; Selcher et al., 1999; Rossi et al., 2008; Delawary et al., 2010).”
Method
Cited by
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
The origin of NMDA receptor hypofunction in schizophrenia
Nakazawa, K., & Sapkota, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107426 · Cited by 275
Over-expression of miR-34a induces rapid cognitive impairment and Alzheimer’s disease-like pathology
Sarkar, S., Engler-Chiurazzi, E. B., Cavendish, J. Z., Povroznik, J. M., Russell, A. E., Quintana, D. D., Mathers, P. H., & Simpkins, J. W. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146327 · Cited by 91
Sun, Y., Huang, J., Chen, Y., Shang, H., Zhang, W., Yu, J., He, L., Xing, C., & Zhuang, C. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104172 · Cited by 73
Metadata
- Authors
- Suryavanshi, P. S., Ugale, R. R., Yilmazer‐Hanke, D., Stairs, D. J., & Dravid, S. M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-01-13
- Volume
- 171
- Issue
- 3
- Pages
- 799-809
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1551425670
- Cited by
- 96
- References
- 18
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.